Prevention and Treatment of Hepatitis Virus Infections in Hematopoietic Stem Cell Transplant Recipients
2009

Preventing and Treating Hepatitis Infections in Stem Cell Transplant Recipients

publication Evidence: moderate

Author Information

Author(s): Chakrabarti Suparno, Mukherjee Somnath, Manashi Chakrabarti

Primary Institution: Manashi Chakrabarti Foundation For Blood Disorders, Kolkata, INDIA

Hypothesis

What are the best strategies for preventing and treating hepatitis B and C infections in hematopoietic stem cell transplant recipients?

Conclusion

Effective prevention and management strategies can minimize complications and improve outcomes for stem cell transplant recipients infected with hepatitis B and C.

Supporting Evidence

  • Over 350 million people are HBV carriers worldwide, with varying prevalence across regions.
  • HBV reactivation post-transplant can lead to severe complications if not monitored closely.
  • Preemptive antiviral therapy can significantly reduce the incidence of HBV reactivation.

Takeaway

Hepatitis B and C can cause serious problems for patients who receive stem cell transplants, but there are ways to prevent and treat these infections to help keep patients safe.

Methodology

The article reviews current guidelines and recommendations for screening, prevention, and treatment of hepatitis infections in stem cell transplant recipients.

Limitations

Limited data on the long-term effects of hepatitis infections in stem cell transplant recipients and the effectiveness of newer antiviral agents.

Digital Object Identifier (DOI)

10.4084/MJHID.2009.017

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication